Long-term outcomes after septal reduction therapy for obstructive hypertrophic cardiomyopathy: a nationwide cohort study
European Heart Journal Open · 05.03.2026 · 6 (2)
DOI: 10.1093/ehjopen/oeag053 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift European Heart Journal Open, online erschienen am 25.03.2026. Verfasst von Andreas Schelldorfer und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Cantonal Hospital Aarau, Tellstrasse 25, 5001 Aarau, Switzerland. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Aims
With cardiac myosin inhibitors emerging as a novel pharmacological option instead of septal reduction therapies (SRT) in obstructive hypertrophic cardiomyopathy (HCM), contemporary data on national long-term outcomes after SRT are needed. Methods and results In this nationwide cohort study from 2015 to 2021, patients with obstructive HCM undergoing SRT (surgical myectomy or transcoronary ablation of septal hypertrophy) were 1:8 propensity score-matched with non-obstructive HCM patients or surgical controls undergoing appendectomy without heart disease in recent records. As assessed in time-to-event analyses, the primary outcome was a composite of all-cause mortality after discharge and rehospitalization for heart failure. After matching, 125 patients with obstructive HCM hospitalized for SRT were compared to 743 patients hospitalized with non-obstructive HCM. The incidence rate (IR) of the primary outcome was lower in the SRT group {12.62 vs. 74.86 per 1000 patient-years (py); hazard ratio (HR), 0.17 [95% confidence interval (CI), 0.07–0.42]; median follow-up 31 months}. In the second comparison, 126 patients with obstructive HCM undergoing SRT were matched to 560 surgical controls without heart disease undergoing laparoscopic appendectomy. The IR of the primary outcome after SRT was comparable to that of surgical controls without heart disease [12.61 vs. 8.09 per 1000 py; HR, 1.53 (95% CI, 0.56–4.18); median follow-up 41 months].
Conclusion
In this nationwide cohort study, SRT was associated with a lower incidence of all-cause mortality after discharge and rehospitalization for heart failure compared to patients hospitalized with non-obstructive HCM, with an incidence comparable to surgical controls without heart disease.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiology, Cantonal Hospital Aarau, Tellstrasse 25, 5001 Aarau, Switzerland.
- Medical University Department, Cantonal Hospital Aarau, Tellstrasse 25, 5001 Aarau, Switzerland.
- University Hospital of Child and Adolescent Psychiatry and Psychotherapy, Bolligenstrasse 111, 3000 Bern 60, Switzerland.
- Arrhythmia and Electrophysiology, Department of Cardiology, University Heart Center, University Hospital Zurich, Rämistrasse 100, 8091 Zurich, Switzerland.
- Medical Faculty, University of Basel, Klingelbergstrasse 61, 4056 Basel, Switzerland.
- Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, 1620 Tremont St, Suite 3030, Boston, MA 02120, USA.
ORCID-Profile: Andreas Schelldorfer, Laurent M Haegeli, H Yakup Yakupoglu
Zitieren
APA
Schelldorfer, A., Laager, R., Haegeli, L. M., Schuetz, P., Kutz, A., & Yakupoglu, H. Y. (2026). Long-term outcomes after septal reduction therapy for obstructive hypertrophic cardiomyopathy: a nationwide cohort study. European Heart Journal Open, 6(2). https://doi.org/10.1093/ehjopen/oeag053
Vancouver
Schelldorfer A, Laager R, Haegeli LM, Schuetz P, Kutz A, Yakupoglu HY. Long-term outcomes after septal reduction therapy for obstructive hypertrophic cardiomyopathy: a nationwide cohort study. European Heart Journal Open. 2026;6(2). doi:10.1093/ehjopen/oeag053
BibTeX
@article{Schelldorfer2026,
author = {Schelldorfer, Andreas and Laager, Rahel and Haegeli, Laurent M and Schuetz, Philipp and Kutz, Alexander and Yakupoglu, H Yakup},
title = {Long-term outcomes after septal reduction therapy for obstructive hypertrophic cardiomyopathy: a nationwide cohort study},
journal = {European Heart Journal Open},
year = {2026},
volume = {6},
number = {2},
doi = {10.1093/ehjopen/oeag053}
}
EUVIMED